HDAC9 and neoplasm: The criteria for selecting genes for validation were both their presumed relevance in the DNA damage response and previous indications of regulation by an HDAC inhibitor [22]–[24], [28], [41], and additionally, in order to find ‘tumor-specific’ markers, omitting genes that typically might be associated with leukocyte biology.